Stimulation of degranulation from human eosinophils by platelet-activating factor.
Platelet-activating factor (PAF) is a highly active mediator which has been implicated in allergic inflammation and bronchial asthma, possibly by interacting with eosinophils. We have examined the effect of PAF on activation of purified human eosinophils as measured by degranulation (eosinophil peroxidase, eosinophil cationic protein, arylsulfatase B, beta-glucuronidase, and alkaline phosphatase) and oxidative metabolism (superoxide anion production). PAF induced enzyme release at concentrations ranging from 1 pM to 10 microM in a rapid (t1/2 5 to 8 min), Ca2+-dependent and noncytotoxic manner from both the specific and small granules, whereas its biologic precursor and metabolite, lyso-PAF, had no effect. For all enzymes, maximal enzyme release occurred at 100 nM PAF with a mean ED50 value of 1.47 +/- 0.4 nM. At this concentration the mean percentage of total enzyme release by PAF from specific granules was 20.3 +/- 1.6% (17.9% for eosinophil peroxidase, 20.6% for beta-glucuronidase, 22.4% for alkaline phosphatase) and 28.8 +/- 2.2% from small granules (arylsulfatase B). Calcium ionophore A23187, PMA, and opsonized zymosan also induced eosinophil degranulation but their peak effect after 10-min incubation with maximal release 14.7%, 12.9%, or 14.1%, respectively, was lower when compared with PAF. Incubation of eosinophils with the PAF-antagonist WEB 2086 led to a parallel shift of the dose-response curve to the right, indicating a competitive antagonism. PAF also caused generation of superoxide anions by human eosinophils but this occurred at higher concentrations of PAF (1 microM to 30 microM) with an ED50 of 8.4 +/- 0.9 microM. Again, this effect was competitively inhibited by WEB 2086. These studies demonstrate that PAF activates human eosinophils to release granule constituents and generate superoxide anions. Since both PAF and eosinophil products are associated with pathogenesis of bronchial asthma our findings may be of particular pathophysiologic relevance.
Kroegel
C
C
Department of Thoracic Medicine, National Heart and Lung Institute, London, United Kingdom.
Yukawa
T
T
Dent
G
G
Venge
P
P
Chung
K F
KF
Barnes
P J
PJ
D000469:Alkaline Phosphatase / Q000097:blood; D001381:Azepines / Q000494:pharmacology; D002118:Calcium / Q000502:physiology; D003594:Cytoplasmic Granules / Q000201:enzymology / Q000378:metabolism*; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000201:enzymology / Q000378:metabolism*; D005110:Extracellular Space / Q000502:physiology; D005966:Glucuronidase / Q000097:blood; D006801:Humans; D007700:Kinetics; D010544:Peroxidases / Q000097:blood; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism; D014227:Triazines / Q000494:pharmacology; D014230:Triazoles
D001381:Azepines; D010972:Platelet Activating Factor; D014227:Triazines; D014230:Triazoles; C052518:WEB 2086; D013481:Superoxides; D047209:Eosinophil Peroxidase; D010544:Peroxidases; D000469:Alkaline Phosphatase; D005966:Glucuronidase; D002118:Calcium